Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cellect Biotechnology Ltd ADR (APOP)

Cellect Biotechnology Ltd ADR (APOP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,872
  • Shares Outstanding, K 977
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,620 K
  • 60-Month Beta 1.87
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.33
Trade APOP with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.28
  • Most Recent Earnings N/A on 08/24/21
  • Latest Earnings Date 11/19/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.55 +4.96%
on 10/26/21
19.44 -32.25%
on 09/30/21
-5.32 (-28.77%)
since 09/28/21
3-Month
12.55 +4.96%
on 10/26/21
35.52 -62.92%
on 09/03/21
-3.27 (-19.89%)
since 07/28/21
52-Week
6.64 +98.34%
on 11/02/20
35.52 -62.92%
on 09/03/21
+6.37 (+93.68%)
since 10/28/20

Most Recent Stories

More News
Cellect Biotechnology Announces Record Date and Distribution Date for CVRs in Connection with Strategic Merger with Quoin Pharmaceuticals

Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”) (the “Company”), announced today the record date and...

APOP : 13.17 (+0.38%)
Cellect Biotechnology Announces Shareholder Approval of Strategic Merger with Quoin Pharmaceuticals

Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held...

APOP : 13.17 (+0.38%)
Cellect Biotechnology Announces the ApoGraft™ Bone Marrow Transplantation of First Patient in U.S.

Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX

APOP : 13.17 (+0.38%)
Cellect Biotechnology Reports Second Quarter 2021 Financial and Operating Results

Strategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter

APOP : 13.17 (+0.38%)
The Securities and Exchange Commission Declared Cellect Biotechnology’s Registration Statement Filed on Form F-4 Effective in Connection with its Previously Announced Strategic Merger with Quoin Pharmaceuticals

Special General Meeting of Shareholders Scheduled for September 19, 2021

APOP : 13.17 (+0.38%)
Cellect Biotechnology Files Registration Statement in Connection with Proposed Strategic Merger Agreement with Quoin Pharmaceuticals

Transaction Expected to Close in the 2021 Third Quarter

APOP : 13.17 (+0.38%)
Cellect Biotechnology Reports Top Line Data from Phase 1/2 Clinical Trial

Results Support Ongoing Clinical Development of ApoGraft in U.S.

APOP : 13.17 (+0.38%)
Cellect Biotechnology Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

TEL AVIV, Israel, March 29, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today reported...

APOP : 13.17 (+0.38%)
Cellect Biotechnology and Quoin Pharmaceuticals Announce Strategic Merger

Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger

APOP : 13.17 (+0.38%)
Cellect Biotechnology Reports Third Quarter Financial and Operating Results; Recent Developments Position Company to Accelerate Progress in 2021

Promising Progress on Clinical D evelopment Progress , Collaboration s and Partnering

APOP : 13.17 (+0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Cellect Biotechnology Ltd. offers biomedical services. It provides stem cell transplantation, disease management, regenerative medicine, clinical research and other services. Cellect Biotechnology Ltd. is based in TEL AVIV, Israel.

See More

Key Turning Points

3rd Resistance Point 13.60
2nd Resistance Point 13.48
1st Resistance Point 13.33
Last Price 13.17
1st Support Level 13.06
2nd Support Level 12.94
3rd Support Level 12.79

See More

52-Week High 35.52
Fibonacci 61.8% 24.49
Fibonacci 50% 21.08
Fibonacci 38.2% 17.67
Last Price 13.17
52-Week Low 6.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar